Skip to content

Effect of Erchonia Laser on Erectile Dysfunction

A Pilot Evaluation of the Effect of the Erchonia® HLS™ on Individuals With Erectile Dysfunction

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05371951
Enrollment
0
Registered
2022-05-12
Start date
2021-10-05
Completion date
2023-03-01
Last updated
2023-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Brief summary

This study is to see if applying low-level laser light can provide improvement in erectile dysfunction

Detailed description

The purpose of this pilot study is to determine the effectiveness of the Erchonia® HLS™, manufactured by Erchonia Corporation (the Company), in providing improvement in erectile dysfunction.

Interventions

84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.

Sponsors

Erchonia Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male between 40 and 80 years old * Known or suspected vasculogenic ED based on clinical history * In an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment * Suffering from ED for at least 6 months * Testosterone level between 300 - 1000ng/dL within one month prior to enrollment * Hgb A1C less than or equal to 8% within one month prior to enrollment * Total IIEF-EF scores between 8-25 * EHS score greater than or equal to

Exclusion criteria

* ED due to radical prostatectomy, prior pelvic surgery, or radiation therapy to the pelvis within 12 months prior to enrollment * Men with known neurogenic or psychogenic ED * Anatomic malformations of the penis including Peyronie's disease * Testosterone greater than 300ng/dL or 1000ng/dL * Hgb A1C greater than 8% * International Normalized Ratio greater than 2.5, and men on any blood thinners other than 81mg aspirin * Active testicular or prostate cancer

Design outcomes

Primary

MeasureTime frameDescription
Total Score on the International Index of Erectile Function - Erectile Function6 weekThe International Index of Erectile Function - Erectile Function ( domain score is a patient questionnaire (six questions) used to measure various aspects of erectile performance and assess disease severity in efficacy trials concerning ED. The International Index of Erectile Function - Erectile Function has a minimum score of 0 and max of 30, higher scores mean a better outcome

Secondary

MeasureTime frameDescription
Total Erection Hardness Score6 weekThe Erection Hardness Score is a single-item scale that has demonstrated good psychometric properties for assessing erectile function in patients. The EHS has desirable measurement properties, including being highly responsive to treatment. This one-item PRO is robust and easy to use for evaluating erection hardness. The Total Erection Hardness Score has a minimum possible score of 0 and max of 4, higher scores mean a better outcome

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026